Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05UQD
|
|||
| Former ID |
DCL000188
|
|||
| Drug Name |
Omapatrilat
|
|||
| Synonyms |
BMS-186716; Omapatrilat (JAN/USAN/INN); (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Terminated | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H24N2O4S2
|
|||
| Canonical SMILES |
C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O
|
|||
| InChI |
1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
|
|||
| InChIKey |
LVRLSYPNFFBYCZ-VGWMRTNUSA-N
|
|||
| CAS Number |
CAS 167305-00-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135660
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Modulator | [1] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [1] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| ACE Inhibitor Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.